Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Clinical trial NCT03161223 · RECRUITING
Trial details
- NCT number
- NCT03161223
- Sponsor
- University of Virginia
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-30
- Primary completion
- 2023-02-01
- Enrollment
- 148
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.